- Stocks
- Healthcare
- NYSE: ABBV

Price (delayed)

$135.21

Market cap

$239.04B

P/E Ratio

32.58

Dividend/share

$5.31

EPS

$4.15

Enterprise value

$307.57B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate

ABBV's revenue is up by 36% year-on-year and by 2.7% since the previous quarter

ABBV's gross profit is up by 34% year-on-year and by 6% since the previous quarter

ABBV's P/E is 34% above its 5-year quarterly average of 24.3 but 3.3% below its last 4 quarters average of 33.7

The EPS has grown by 13% from the previous quarter but it has contracted by 13% YoY

What are the main financial stats of ABBV

Market
Valuations
Earnings

Shares outstanding

1.77B

Market cap

$239.04B

Enterprise value

$307.57B

Price to earnings (P/E)

32.58

Price to book (P/B)

17.63

Price to sales (P/S)

4.34

EV/EBIT

31.93

EV/EBITDA

16.86

EV/Sales

5.58

Revenue

$55.17B

EBIT

$9.63B

EBITDA

$18.24B

Free cash flow

$21.68B

Per share
Balance sheet
Liquidity

EPS

$4.15

Free cash flow per share

$12.25

Book value per share

$7.67

Revenue per share

$31.17

TBVPS

$22.09

Total assets

$148.86B

Total liabilities

$135.28B

Debt

$80.72B

Equity

$13.55B

Working capital

$424M

Debt to equity

5.96

Current ratio

1.01

Quick ratio

0.75

Net debt/EBITDA

3.76

Margins
Efficiency
Dividend

EBITDA margin

33.1%

Gross margin

67.7%

Net margin

13.7%

Operating margin

30.1%

Return on assets

5%

Return on equity

57%

Return on invested capital

11.9%

Return on capital employed

8%

Return on sales

17.5%

Dividend yield

3.93%

DPS

$5.31

Payout ratio

128%

How has the AbbVie stock price performed over time

Intraday

-1.15%

1 week

-1.52%

1 month

4.39%

1 year

20.53%

YTD

-0.14%

QTD

-0.14%

How have AbbVie's revenue and profit performed over time

Revenue

$55.17B

Gross profit

$37.36B

Operating income

$16.6B

Net income

$7.53B

Gross margin

67.7%

Net margin

13.7%

The operating income has grown by 44% YoY and by 7% from the previous quarter

ABBV's revenue is up by 36% year-on-year and by 2.7% since the previous quarter

ABBV's gross profit is up by 34% year-on-year and by 6% since the previous quarter

The net margin has declined by 25% year-on-year but it rose by 10% since the previous quarter

What is AbbVie's growth rate over time

What is AbbVie stock price valuation

P/E

32.58

P/B

17.63

P/S

4.34

EV/EBIT

31.93

EV/EBITDA

16.86

EV/Sales

5.58

ABBV's P/E is 34% above its 5-year quarterly average of 24.3 but 3.3% below its last 4 quarters average of 33.7

The EPS has grown by 13% from the previous quarter but it has contracted by 13% YoY

ABBV's price to book (P/B) is 21% higher than its last 4 quarters average of 14.6

AbbVie's equity has decreased by 11% YoY but it has increased by 8% from the previous quarter

ABBV's revenue is up by 36% year-on-year and by 2.7% since the previous quarter

ABBV's P/S is 17% above its last 4 quarters average of 3.7 and 6% above its 5-year quarterly average of 4.1

How efficient is AbbVie business performance

The ROE has plunged by 72% YoY but it has grown by 17% from the previous quarter

The ROS has contracted by 29% YoY but it has grown by 11% from the previous quarter

AbbVie's return on assets has decreased by 19% YoY but it has increased by 11% QoQ

AbbVie's ROIC has increased by 17% from the previous quarter but it has decreased by 9% YoY

What is ABBV's dividend history

DPS

$5.31

Dividend yield

3.93%

Payout ratio

128%

Recent dividends

How did AbbVie financials performed over time

AbbVie's total assets is 10% higher than its total liabilities

The quick ratio has grown by 15% from the previous quarter and by 10% YoY

ABBV's current ratio is up by 11% since the previous quarter and by 6% year-on-year

AbbVie's equity has decreased by 11% YoY but it has increased by 8% from the previous quarter

The company's debt to equity fell by 9% QoQ but it rose by 4.6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.